Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

01 09-12+biotech+showcase+presentation(1)

175 views

Published on

  • Be the first to comment

  • Be the first to like this

01 09-12+biotech+showcase+presentation(1)

  1. 1. Jim Joyce Chairman, CEO January 9, 2012My presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whetherand when our products are successfully developed and introduced, market acceptance of the Aethlon ADAPT™ system, the Hemopurifier® andother product offerings, regulatory delays, manufacturing delays, and other risks detailed in our sec filings accessible at www. Sec.gov.
  2. 2. We create medical devices to address unmetmedical needs in cancer, infectious disease,and other life-threatening conditions
  3. 3. The transition from development-stage to revenue-stage organization
  4. 4. Adaptive Dialysis-like Affinity Platform Technology
  5. 5. The intersection of medical devicetechnology and affinity drug mechanisms Mabs Dialysis ADAPT Lectins Plasmapheresis Aptamers
  6. 6. Target binding isEffective target separation highly selective No target discrimination Toxicity Limits Dosing
  7. 7. High specificityIndiscriminate ADAPT Toxicity Effective separation
  8. 8. The Hemopurifier®An Aethlon ADAPT™ Therapy
  9. 9. Aethlon ADAPT™ therapies seamlessly integrateinto the infrastructure of dialysis and CRRTmachines located in hospitals in clinics worldwide
  10. 10. Aethlon ADAPT™ therapies provide access to the entire circulatory system•  Rapid real-time access to single or multiple therapeutic targets in as little as 15 minutes•  Adjunct to improve SOC therapy benefit without adding drug toxicity or interaction risks•  Able to address targets beyond the reach of drugs
  11. 11. The future is home based therapy
  12. 12. The Aethlon Hemopurifier®•  The lead Aethlon ADAPT™ treatment candidate•  Broad-spectrum capture of viral pathogens and immunosuppressive exosomes underlying cancer and infectious disease•  Compelling HCV & HIV/AIDS treatment outcomes in ESRD patient population
  13. 13. •  The Drug Industry •  Provides medical device pathway for affinity drug agents •  $5 million vs. $500 million •  Repurposes approved, clinical stage & previous clinical dropouts•  Military & Government Health Agencies •  Seeking innovative therapeutic solutions
  14. 14. Viral Load Reduction by Drugs Alone $!!"# ,!"# +!"#!"#$%&(")*+"+%,("-./" *!"# )!"# (!"# !"# &!"# %!"# $!"# !"# !# $# %# &# # (# )# *# 0%12"3/456"
  15. 15. Viral Load Reduction by Hemopurifier Alone $!!"# ,!"# +!"#!"#$%&(")*+"+%,("-./" *!"# )!"# (!"# !"# &!"# %!"# $!"# !"# !# $# %# &# # (# )# *# 0%12"3/456"
  16. 16. Viral Load Reduction by Drugs and Hemopurifier in Combination $!!"# ,!"# -.#/0123#45#607/89# :0123#8;.<=#>0=/?@A=/# +!"# :0123#B#45#60#>0=/?@A=/# :0123#8;.<=#.C3#!"#$%&(")*+"+%,("-./" *!"# )!"# (!"# !"# &!"# %!"# $!"# !"# !# $# %# &# # (# )# *# 0%12"3/456"
  17. 17. Comparasion to RVR Achievement 7000000 6000000 5000000Viral Load ul/ml 4000000 SOC Alone 3000000 SOC + Hemopurifier® 2000000 1000000 0 Day 1 Pre 3 post 7 post D-10 D-14 D-17 D-21 D-24 30 post Day
  18. 18. ContactJim JoyceChairman, CEO8910 University Center LaneSan Diego, California 92122858.459.7800 x301jj@aethlonmedical.com

×